PTC Therapeutics, Inc. Current Liabilities
PTC Therapeutics, Inc. (PTCT) had Current Liabilities of $771.07 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-30
- 2026-06-30: Liabilities, Current $771.07M.
- 2026-03-31: Liabilities, Current $923.60M.
- 2025-12-31: Liabilities, Current $968.43M.
- 2025-09-30: Liabilities, Current $866.25M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $771.07M 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $923.60M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $968.43M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $866.25M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $627.81M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $595.39M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $580.98M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $610.71M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $609.80M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $574.55M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $603.10M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $492.12M 10-Q · filed 2023-10-26 | |
| 2023-06-30 | $476.34M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $441.63M 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $406.24M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $420.08M 10-Q · filed 2022-10-27 | |
| 2022-06-30 | $567.37M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $476.78M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $509.35M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $465.26M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $290.96M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $250.95M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $277.33M 10-K · filed 2022-02-22 | |
| 2020-09-30 | $253.82M 10-Q · filed 2020-10-29 | |
| 2020-06-30 | $201.84M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $217.67M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $235.86M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $183.50M 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $173.96M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $143.05M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $166.80M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $114.92M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $86.47M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $72.72M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $82.05M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $71.90M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $67.98M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $45.42M 10-Q · filed 2017-05-08 | |
| 2016-12-31 | $49.62M 10-K · filed 2018-03-06 | |
| 2016-09-30 | $48.93M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $42.91M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $43.89M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $45.39M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $31.70M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $23.08M 10-Q · filed 2015-07-31 | |
| 2015-03-31 | $23.91M 10-Q · filed 2015-05-05 | |
| 2014-12-31 | $32.48M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $17.26M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $11.58M 10-Q · filed 2014-08-07 | |
| 2014-03-31 | $9.24M 10-Q · filed 2014-05-06 | |
| 2013-12-31 | $13.13M 10-K · filed 2015-03-02 | $13.13M 10-K · filed 2014-03-06 |
| 2013-09-30 | $13.92M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $19.79M 10-Q · filed 2013-08-13 | |
| 2012-12-31 | $28.16M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |